Blocking immunosurveillance of B‐cell lymphoma and myeloma via CD4 T cell is a suggestive pathophysiological pathway due to the increased risk of cancer in long‐term use of fingolimod in patients.8 This evidence concerns the gene CD4 and plasma cell myeloma.